{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2
  ],
  "modelUsed": "gemini-3-flash-preview",
  "metadata": {
    "studyName": "A Phase III, randomized, double-blind, placebo-controlled study of PDR001 in combination with dabraf",
    "titles": [
      {
        "id": "title_1",
        "text": "A Phase III, randomized, double-blind, placebo-controlled study of PDR001 in combination with dabrafenib and trametinib in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma",
        "type": {
          "code": "Official Study Title",
          "codeSystem": "USDM",
          "decode": "Official Study Title"
        },
        "instanceType": "StudyTitle"
      }
    ],
    "identifiers": [
      {
        "id": "sid_1",
        "text": "CPDR001F2301",
        "scopeId": "org_1",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "SponsorProtocolNumber",
          "codeSystem": "USDM",
          "decode": "Sponsor Protocol Number"
        }
      }
    ],
    "organizations": [
      {
        "id": "org_1",
        "name": "Novartis",
        "type": {
          "id": "d7bc28ed-53fd-4220-9cc9-93f30c163a00",
          "code": "C54086",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Pharmaceutical Company",
          "instanceType": "Code"
        },
        "identifier": "Novartis",
        "identifierScheme": "DUNS",
        "instanceType": "Organization"
      }
    ],
    "roles": [
      {
        "id": "role_1",
        "name": "Sponsor",
        "code": {
          "code": "Sponsor",
          "codeSystem": "USDM",
          "decode": "Sponsor"
        },
        "organizationIds": [
          "org_1"
        ],
        "instanceType": "StudyRole"
      }
    ],
    "indications": [
      {
        "id": "ind_1",
        "name": "Melanoma",
        "isRareDisease": false,
        "instanceType": "Indication",
        "description": "BRAF V600 mutation-positive unresectable or metastatic melanoma"
      }
    ],
    "studyPhase": {
      "code": "Phase3",
      "codeSystem": "USDM",
      "decode": "Phase3"
    },
    "studyType": "Interventional"
  },
  "rawResponse": {
    "titles": [
      {
        "id": "title_1",
        "text": "A Phase III, randomized, double-blind, placebo-controlled study of PDR001 in combination with dabrafenib and trametinib in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma",
        "type": {
          "code": "OfficialStudyTitle",
          "codeSystem": "http://www.cdisc.org/USDM/titleType",
          "decode": "Official Study Title"
        },
        "instanceType": "StudyTitle"
      }
    ],
    "identifiers": [
      {
        "id": "sid_1",
        "text": "CPDR001F2301",
        "identifierType": "SponsorProtocolNumber",
        "issuingOrganization": "Novartis",
        "instanceType": "StudyIdentifier"
      }
    ],
    "organizations": [
      {
        "id": "org_1",
        "name": "Novartis",
        "type": {
          "code": "Sponsor",
          "codeSystem": "http://www.cdisc.org/USDM/organizationType",
          "decode": "Sponsor"
        },
        "role": "Sponsor",
        "instanceType": "Organization"
      }
    ],
    "studyPhase": {
      "code": "Phase3",
      "codeSystem": "http://www.cdisc.org/USDM/studyPhase",
      "decode": "Phase 3"
    },
    "studyType": "Interventional",
    "indication": {
      "id": "ind_1",
      "name": "Melanoma",
      "description": "BRAF V600 mutation-positive unresectable or metastatic melanoma",
      "instanceType": "Indication"
    }
  }
}